Changchun High-Tech Industry Group Co Ltd

The company maintains a strong liquidity position with a current ratio of 4.82, indicating a robust ability to meet short-term obligations. However, its net cash position is negative after subtracting total debt, signaling potential liquidity risk. The debt-to-equity ratio of 0.09 suggests a conservative capital structure, with minimal reliance on debt financing. The operating cash flow of 1.98 billion CNY supports this liquidity, although capital expenditures of -982.49 million CNY indicate ongoing investment in operations.

Profitability metrics show a return on equity of 3.93% and a return on assets of 2.87%, both below the industry median for pharmaceutical firms. The gross profit margin of 85.6% is strong, but the operating margin of 32.4% and net margin of 24.9% suggest pressure from operating expenses and taxes. These returns are in line with the company's capital-light business model but lag behind top performers in the sector.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory risks. No material revenue is attributed to international markets, and the company's operations are entirely within China.

Growth trajectory is modest, with no disclosed revenue growth rates or forward-looking guidance. Analysts project a mean price target of 124.96 CNY, with a median of 111.34 CNY, but no consensus on near-term revenue acceleration. The company's capital expenditures suggest ongoing investment, but the negative net cash position limits expansion capacity.

Risk factors include liquidity constraints due to negative net cash and a medium liquidity risk rating. The dilution risk is low, with no near-term pressure from share issuance or convertible debt. However, the company's reliance on a single business segment and geographic concentration increases vulnerability to sector-specific shocks.

Recent events include no material filings or transcripts disclosed in the latest data. Analysts have issued one strong-buy recommendation and no buy or hold ratings, indicating cautious optimism about the company's long-term prospects.

Changchun High-Tech Industry Group Co Ltd (000661.SZ) has been formally classified within the Healthcare economic sector, with its primary activity identified as Pharmaceuticals & Medical Research. This taxonomic update provides a clearer definition of the company’s operational focus, aligning its market positioning with the broader healthcare industry landscape. In terms of risk profile, the company’s dilution risk has been assessed as low. This assessment suggests that the likelihood of significant share count expansion or value erosion through equity issuance is currently minimal, offering a degree of stability for existing shareholders regarding ownership concentration. Conversely, the liquidity risk for Changchun High-Tech Industry Group has been categorized as medium. This indicates that while the stock is not facing immediate illiquidity crises, there may be moderate constraints on trading volume or ease of execution that investors should monitor, particularly during periods of market stress. These updates to the company’s sector classification and risk metrics provide a more structured framework for evaluating Changchun High-Tech Industry Group. By establishing its identity within the pharmaceutical and medical research space and defining its specific risk parameters, stakeholders can better contextualize the firm’s performance relative to its industry peers.

Debt-to-equity ratio of 0.09 is half the cohort median of 0.18, reflecting a conservative capital structure.

Cash conversion of 2.3 is well above the cohort median of 0.95, highlighting robust cash generation capabilities.

Analyst consensus suggests 48.5% upside to the mean price target of 124.96 CNY from current levels.

Long-term debt increased to 2.14 billion CNY in FY2026, rising alongside deteriorating cash flow and earnings.

Revenue ¥12.08B, −10,3% YoY; Operating income −88,1% YoY.

• ▍Revenue ¥12.08B, −10,3% YoY
• ▍Operating income −88,1% YoY
• ▍Net income −94,0% YoY
• ▍Free cash flow −265,6% YoY
• ▍Net margin 1.3%

Revenue ¥13.47B, −7,5% YoY; Operating income −41,1% YoY.

• ▍Revenue ¥13.47B, −7,5% YoY
• ▍Operating income −41,1% YoY
• ▍Net income −43,0% YoY
• ▍Free cash flow −125,0% YoY
• ▍Net margin 19.2%

Revenue ¥14.57B, +15,3% YoY; Operating income +12,5% YoY.

• ▍Revenue ¥14.57B, +15,3% YoY
• ▍Operating income +12,5% YoY
• ▍Net income +9,5% YoY
• ▍Free cash flow +34,7% YoY
• ▍Net margin 31.1%

Revenue ¥12.63B, +17,5% YoY; Operating income +5,4% YoY.

• ▍Revenue ¥12.63B, +17,5% YoY
• ▍Operating income +5,4% YoY
• ▍Net income +10,2% YoY
• ▍Free cash flow +24,8% YoY
• ▍Net margin 32.8%

Revenue ¥10.75B; Operating income ¥4.71B.

• ▍Revenue ¥10.75B
• ▍Operating income ¥4.71B
• ▍Net margin 35.0%